Print
On January 10, 2021, clinical trials of the use of cannabidiol (CBD) in the treatment of complications of coronavirus began at Rabin Medical Center, Petach Tikva, Israel.
Current treatment for COVID-19 (coronavirus) is mostly supportive, and respiratory failure due to acute respiratory distress syndrome (ARDS) is the leading cause of death.
Cytokines and chemokines are believed to play an important role in immunity and immunopathology during viral infections. Patients with severe COVID-19 have higher serum levels of pro-inflammatory cytokines and chemokines compared to people with mild disease or healthy people.
Cannabidiol (CBD) has potent anti-inflammatory and immunosuppressive properties. In a series of Phase 2 trials involving over 100 patients, a team of researchers from Rabin Medical Center, Israel was able to demonstrate the safety and effectiveness of CBD.
Based on this data, a new study plans to test the cytokine profile, safety and efficacy of CBD treatment in patients with severe and critical COVID-19 infection.
Research objectives:
To evaluate the effect of CBD on the cytokine profile in patients with severe and critical COVID-19 infection and to study the safety and efficacy of CBD treatment in patients with severe and critical COVID-19 lung infection.
Methods:
Cannabidiol oil solution (5%), will be given orally in a 150 mg dose (in two divided doses) for 14 days or until discharge (earliest). This is roughly 2mg / kg bw and the dosage is based on safety data from over 100 patients in phase 2 trials. The duration of treatment can be extended to 28 days at the discretion of the clinician.
The study is scheduled to be completed by December 2021.